文章摘要
姜观书,庞 雁,吴群英,崔伟伟,曾志兰.西格列汀通过增加肾组织中SOCS 1和Podocalyxin的表达改善糖尿病肾病大鼠肾功能[J].,2020,(18):3434-3438
西格列汀通过增加肾组织中SOCS 1和Podocalyxin的表达改善糖尿病肾病大鼠肾功能
Sitagliptin Improves Renal Function of Diabetic Nephropathy Rats by Increasing the Expression of SOCS 1 and Podocalyxin in the Renal Tissue
投稿时间:2020-04-06  修订日期:2020-04-30
DOI:10.13241/j.cnki.pmb.2020.18.007
中文关键词: 西格列汀  细胞因子信号传导负调控因子1  Podocalyxin  糖尿病肾病  肾功能
英文关键词: Sitagliptin  SOCS 1  Podocalyxin  Diabetic nephropathy  Renal function
基金项目:江苏省妇幼保健协会科研课题立项(FYX201808)
作者单位E-mail
姜观书 南京中医药大学附属中西医结合医院(江苏省中医药研究院)药学部 江苏 南京 210000 jgs13805162077@163.com 
庞 雁 南京中医药大学附属中西医结合医院(江苏省中医药研究院)药学部 江苏 南京 210000  
吴群英 江阴市人民医院妇科 江苏 江阴 214400  
崔伟伟 南京中医药大学附属中西医结合医院(江苏省中医药研究院)药学部 江苏 南京 210000  
曾志兰 南京中医药大学附属中西医结合医院(江苏省中医药研究院)药学部 江苏 南京 210000  
摘要点击次数: 737
全文下载次数: 415
中文摘要:
      摘要 目的:探讨西格列汀对糖尿病肾病大鼠肾功能及肾组织中细胞因子信号传导负调控因子1(Suppressors of cytockine signaling, SOCS 1)和足细胞特异蛋白抗体(Podocalyxin)表达的影响。方法:将大鼠随机分为4组:对照组,模型组,西格列汀组和贝那普利组。模型组、西格列汀组和贝那普利组采用腹腔注射链脲佐菌素建立模型,对照组给予腹腔注射等量生理盐水。造模成功后,西格列汀组(n=8)和贝那普利组(n=8)分别灌胃给予7 mg/kg/d的西格列汀和贝那普利。模型组(n=8)和对照组(n=10)均给予等体积的蒸馏水灌胃,连续8周。检测并对比各组大鼠代谢相关指标,肾组织纤维化程度指标,肾组织中炎症因子水平以及Podocalyxin、SOCS 1和结蛋白(Desmin)表达。结果:干预8周后,与对照组对比,模型组空腹血糖、糖化血红蛋白、甘油三酯、总胆固醇、24 h尿蛋白排泄率、肌酐、体重、肾组织转化生长因子-β1(Transforming growth factor,TGF-β1)、白介素(Interleukin,IL)-6、IL-1 β、SOCS 1和Desmin水平均显著增加,Ⅳ型胶原蛋白(Collagen-Ⅳ,C-Ⅳ)、纤维连接蛋白(Fibronectin,FN)、层黏连蛋白(Laminin,LN)和Podocalyxin水平显著降低(P<0.05);与模型组对比,西格列汀组和厄贝沙坦组空腹血糖、糖化血红蛋白、甘油三酯、总胆固醇、24 h尿蛋白排泄率、肌酐、体重、肾组织TGF-β1、IL-6、IL-1 β和Desmin水平均显著降低,Podocalyxin和SOCS 1蛋白表达增加(P<0.05)。但厄贝沙坦组与西格列汀组以上各指标对比差异无统计学意义(P>0.05)。结论:西格列汀可能通过增加Podocalyxin和SOCS 1蛋白表达,降低肾组织中炎症因子和Desmin蛋白表达,进而改善糖尿病肾病大鼠肾纤维化和肾功能。
英文摘要:
      ABSTRACT Objective: To investigate the effect of sitagliptin on renal function and the expression of suppressors of cytockine signaling (SOCS 1) and podocalyxin in diabetic nephropathy rats. Methods: The rats were randomly divided into four groups: control group, model group, cigliptin group and benazepril group. The model group, siggliptin group and benazepril group were injected intraperitoneally with streptozotocin to establish the model, while the control group was injected intraperitoneally with the same volume of normal saline. After the model was established successfully, 7 mg / kg / d of cigliptin and benazepril were given by gavage respectively in the cigliptin group (n=8) and benazepril group (n=8). Model group (n=8) and control group (n=10) were given the same amount of distilled water by gavage for 8 weeks. The metabolism related indexes, renal fibrosis index, the level of inflammatory factors in renal tissue and the expression levels of podocalyxin, SOCS1 and Desmin protein were detected and compared. Results: After 8 weeks of intervention, compared with the control group, fasting blood glucose, glycosylated hemoglobin, triglyceride, total cholesterol, 24 h urinary protein excretion rate, creatinine, body weight, transforming growth factor- β1(TGF - β1), interleukin(IL)-6, IL-1 β, SOCS 1 and Desmin were significantly increased, while collagen-Ⅳ(C-Ⅳ), fibronectin(FN), laminin(LN) and podocalyxin were significantly decreased (P<0.05). Compared with the model group, the fasting blood glucose, glycosylated hemoglobin, triglyceride, total cholesterol, 24-h urinary protein excretion rate, creatinine, body weight, TGF - β1, IL-6, IL-1 β and desmin levels were significantly decreased, while the expression of podocalyxin and SOCS 1 protein was significantly increased (P<0.05). However, there was no significant difference between irbesartan group and sitagliptin group (P>0.05). Conclusion: Sitagliptin can improve the renal fibrosis and renal function in diabetic nephropathy rats by increasing the expression of podocalyxin and SOCS1 protein, reducing the expression of inflammatory factors and Desmin protein in renal tissue.
查看全文   查看/发表评论  下载PDF阅读器
关闭